BioRestorative Therapies (BRTX) Accounts Payables (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Accounts Payables for 15 consecutive years, with $859898.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accounts Payables rose 114.24% year-over-year to $859898.0, compared with a TTM value of $859898.0 through Sep 2025, up 114.24%, and an annual FY2024 reading of $483070.0, up 155.07% over the prior year.
  • Accounts Payables was $859898.0 for Q3 2025 at BioRestorative Therapies, up from $609931.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $859898.0 in Q3 2025 and bottomed at $50827.0 in Q4 2021.
  • Average Accounts Payables over 5 years is $312433.9, with a median of $230902.0 recorded in 2024.
  • The sharpest move saw Accounts Payables crashed 88.01% in 2021, then surged 287.17% in 2022.
  • Year by year, Accounts Payables stood at $50827.0 in 2021, then soared by 236.24% to $170902.0 in 2022, then rose by 10.82% to $189389.0 in 2023, then surged by 155.07% to $483070.0 in 2024, then surged by 78.01% to $859898.0 in 2025.
  • Business Quant data shows Accounts Payables for BRTX at $859898.0 in Q3 2025, $609931.0 in Q2 2025, and $599500.0 in Q1 2025.